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Introduction 
 
Definition of bioresources and their importance in biomedical research 
 
An increasing portion of biomedical research relies on the use of bioresources [1], many of 
which are being already embedded in medical practice. Bioresources and a number of 
related objects need to be reminded (box1). These resources are increasingly important in 
the modern era of “omics” medicine [2]: high throughput ‘omics’ platforms require 
material from and generate data on large numbers of both patients and/or healthy 
individuals. It is difficult or impossible, to obtain to do this on an individual basis, and this 
need is being met by contemporary bioresource facilities. Biobanks used for research aim 
at providing reliable and sustainable solutions with respect to several key issues, in order 
to provide high-quality material based on optimized procedures for the various steps, from 
acquisition, processing and storage to transfer procedures [3]. One of those issues 
concerns measuring the actual use of bioresources. 
As more long term clinical and outcome data are generated, the value of a bioresource 
tends to increase exponentially with time. Indeed, data accrual is a major activity of many 
bioresource projects. Also, as research progresses, projects supplied with material will 
return research results (which can include both raw and curated data) to the resource and 
thus enhance the data set available; indeed the data alone may be sufficient to mine and 
answer research questions. Excellent examples are: the Framingham cohort [], variant-
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frequency data in the dbSNP database [4]  which are derived from the analysis of panels of 
DNAs from specific human populations; Genbank [5], OMIM [6], CEPH families [7]…..  
A commitment to share this information with the research community is paramount [8,9]. 
The 2011 joint statement of 17 major national funders sent a powerful signal that research 
resources must be shared to maximize the potential of publicly funded resources 
[4,10,11]. However, an open-access policy for research data needs to be backed up by 
appropriate measures to enable the proper recognition for research resources being used 
in the development of novel scientific knowledge. Failure to do so will have a major 
negative impact on the global sharing vision which funders hope to encourage. Whilst 
promoting measures to improve access to biobanks and databases, we must develop 
policies mandating end-users to recognize and acknowledge the provenance of these 
resources. An appropriate set of tools is needed to implement such policies. Some tools 
currently exist, but an insufficient level of coordination and systematic implementation 
makes it difficult to see their positive impact on the overall organization of scientific 
activities.  
 
 
What are the obstacles for recognition of the work involved in setting up and maintaining 
bioresources? 
Establishing a valuable bioresource requires considerable time and effort. To provide 
appropriate rewards and recognition, it is necessary to be able to measure the 
performance of bioresources and there are various ways to do so, using a range of 
indicators (see Box 2) including management indicators showing that the bioresource is 
efficiently run and well utilized, indicators of the quality of the bioresource at various 
levels (biological samples, annotations and associated data, and search tools), of quantity 
available and of value of the samples or datasets, and indicators of research productivity.  
Since the purpose of the bioresources considered here is to enhance research productivity, 
this last indicator may provide the most reliable assessment of an appropriate use. 
However, each current indicator has serious drawbacks, as outlined in box 3. The process 
of tracking publications and quantifying their impact is not straightforward. To track the 
publications made possible by a bioresource, it is essential that researchers consistently 
acknowledge use of the bioresource by placing a unique and traceable citation in all their 
relevant publications in a defined section of articles. To some extent this is already 
possible, i.e. if researchers acknowledge the bioresource in their articles or refers to 
bioresources’s publications and if the effort is made to search through publications to find 
appropriate acknowledgements. To optimise this process and standardise it, it needs to be 
automated and based on systematic use of traceable and unique resource identifiers to 
support a routine and widely accepted method of assessment. 
 
 
 
 
What are the obstacles for recognition of the work involved in setting up and maintaining 
databases? 
A database differs in many ways from other types of bioresource such as a biospecimen 
bank. The tangible commodity in a database is information, as opposed to the samples, 
cell lines and DNA found in biological samples biobanks. The existence of a physical 
commodity affords biobanks the ability to control the distribution of their resources. This 
facilitates the later collection of data relating to the impact of the distributed items. By 
comparison, databases deal solely in information, with the traditional expectation on the 
part of the end-user that access to the data will be free. A notable exception to the free 
model of data distribution is BIOBASE [12] which charges for the distribution of its own and 
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that of third parties (such as HGMD Professional) with whom it has commercial 
agreements.  
Within the framework of the free-access expectation in which they operate, databases 
have only very limited scope to measure their impact. It is feasible to log visits or “hits” 
to web pages and to broadly identify from where the requests are being made, but it is 
much more difficult to obtain detailed information. Because no contract exists with users, 
it is impossible to impose requirements on users with respect to how they are expected to 
acknowledge their use of the data in publications. However, imposition of a “contract” as 
rudimentary as the need to register to access data would only amount to being a crude 
control measure and would probably be a disincentive for many users. 
Even when authors make an honest attempt to properly acknowledge a database, the 
results can be patchy. Publication of the URL for a database in biomedical papers provides 
some evidence of reuse, but if it is not present in the abstract the URL will not be indexed 
in PubMed or other bibliographic databases. Hence there is a need to establish a clear 
policy on the part of publishers concerning the citation and referencing of database. 
Otherwise, measuring the impact of open-access online database resources will remain an 
imprecise process. 
 
 
The BRIF concept and objectives 
 
To address the above issues, the Bioresource Research Impact Factor (BRIF) was 
introduced in 2003 [13], and later further developed [14,15]. The central aim of the BRIF 
is to construct a quantitative parameter to evaluate bioresources, modeled to some 
degree on the Journal Impact Factor (JIF) [16], and  to provide guidance and methodology 
for optimising recognition of bioresources, their use and their sharing at international 
level. This would make it possible to document: i) the quantitative use of a bioresource, 
ii) the type and the importance of research results involving it, and iii) the scientific and 
management efforts of those who established and made available a bioresource, and 
provide recognition for their institution. Such a framework could be used much more 
rationally than “reputation” for evaluating bioresource activities over time. When taken 
into account in assessing researchers/contributors’ professional results, this would 
increase the quality and sharing of bioresources. 
To implement this concept an international working group has been set up. The working 
group comprises 123 members from 22 countries. Specific tasks have been assigned to 
several sub-groups as presented below.  
 
 
 
 
 
Digital identifier schemes 
 
To address the various issues referred to above concerning identification, bioresources 
need to be assigned actionable digital identifiers or IDs [17]. In order to fulfil the 
requirements of the scholarly record, bioresource ID should be persistent, globally unique 
and citable. The ID  subgroup focuses on exploring and assessing existing and emerging 
technical solutions suitable for bioresource identification, as well as addressing key 
related questions such as what to identify (biobank projects, sample collections, 
databases, datasets) and which international and independent body or bodies should be 
responsible for assigning bioresource ID. 
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It is worth emphasizing here that the aim is not to create a new identifier scheme 
specifically for bioresources. Rather, the aim is to identify frameworks which are already 
established (or well on their way to becoming so) and to subsequently recommend their 
use as appropriate with respect to: i) resource providers (e.g. what type of IDs to use for 
biobank projects, clinical trial registering system or other systems [18]); ii) end users (e.g. 
guidelines from journal editors to authors about how to properly cite biobank projects and 
databases using unique ID). 
Preliminary conclusions of the sub-group are that the field is already moving in the right 
direction in several areas. Notably, the DataCite initiative [19] has established a 
worldwide data registration agency which reuses and extends the Digital Object Identifier 
(DOI) scheme already widely used in the scholarly publishing domain [20,21]. Digital 
records describing bioresources (e.g. sample collections), or borne-digital resources 
(datasets associated with a resource or generated by its use) could well be assigned data 
DOIs. This could be an important step towards treating these important research outputs 
as first-class contributions to science [22].  DOIs could then serve as first-step identifiers 
to be used in the BRIF assessment. 
A highly-related issue is the current lack of global infrastructure for identifying and 
attributing researchers who contribute to bioresources. The centralized contributor ID 
system now being built by the international ORCID initiative [23] will be launched mid-
2012. It seems reasonable to assume that this infrastructure will be at the heart of any 
attribution schemes and therefore very relevant for BRIF in the near future. 
 
Parameters, measures and indicators 
 
To identify the different parameters to take into account when calculating the BRIF, it has 
been decided to focus on two types of entity providing a service to the scientific 
community:  i) biobanks of human biomaterials and ii) databases of information relating to 
human subjects research. The aim is to provide a measure of the extent to which 
bioresources contribute to research. Downstream effects on healthcare and the economy 
will not be assessed. The parameters need to be objective and easily verifiable, and the 
calculation of a BRIF needs to be as simple as possible. A wide range of parameters are 
being considered for inclusion, including some indicators of bioresource quality, value, 
efficiency and research productivity as noted above. The most obvious is a simple metric 
based on citation counts and the traditional notion of journal-level impact. More 
sophisticated factors which incorporate measurements of bioresource quality, value and 
efficiency can also be devised (see Box 4). 
  
 
 
Journal guidelines for resource citing and referencing 
 
A key element for assessing the use and the research impact of bioresources is their 
systematic citation in journal articles. However, we are far from having standards and 
guidelines for the citation of such resources. A specific task is a proposal for sensitizing 
journal editors to BRIF issues and modifying their editorial guidelines accordingly. The 
necessity of recognition by journal editors of the need to properly acknowledge the 
bioresources used, using proper terminology and/or identifiers and agreeing on standards 
of citation (format/marker paper, location(s), institutions, people, etc.) have been 
extensively discussed. As “Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals” [24] already exist, a proposal has been sent to the International Committee of 
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Medical Journal Editors to be considered in a future amendment of these requirements. 
This proposal highlights some additional requirements (Box 5) that may be needed to 
address the editorial problems concerning bioresources. Furthermore, additional actions 
have been planned to sensitize other committees and institutions concerned with editorial 
and ethical issues.  
 
 
Policies for resource access and sharing 
 
Attempting to measure the impact of a bioresource supposes, as its premise, that the 
research resource is actually being used. Use of a biobank (or research database) is 
contingent upon many factors, but the access and sharing policies certainly play a major 
role in facilitating or hindering use. Various components such as the level of constraints 
imposed on users or the level of simplicity/complexity of the procedures to gain access 
are pivotal in creating an environment that will stimulate or discourage use of a given 
bioresource.  
Sharing, access and publication policies, and the agreements that support the 
‘transaction’ of sharing material or data, appear as the appropriate vehicles to consider in 
implementing enforceable means of measuring the impact of a bioresource [25]. Through 
such guidelines or contracts, a bioresource can impose requirements on eventual users 
requirements to empower itself to measure its impact. Let us consider two categories of 
tools that are likely to contribute to the capacity of a bioresource to measure its impact: 
the dissemination and the ‘control’ measures.  
Publications, academic presentations and other less traditional means of disseminating 
research results have a prime importance in measuring the impact of a scientific 
contribution. Bioresources must thus ensure that users will recognize the resources that 
were used in whatever medium of dissemination the researchers choose to communicate 
the results to the scientific community and the public. This recognition must be written in 
such a way as to allow for a systematic search to track uses as described above. 
Bioresources might also consider requiring the users to report on their use (e.g. sending 
their publication or a summary report) back to its source. However, a balance must be 
struck between imposing a series of requirements on users and on bioresource managers 
and still maintaining conditions that foster resource use.  
Another element is the level of control that the bioresource can exercise over the 
secondary use of its material/data. If a bioresource hopes to keep track of the use of its 
content, it must ensure that all eventual users will comply with its dissemination 
requirements. This is particularly a challenge for research databases where the data can 
be copied and circulated easily and ad infinitum. In a context where international 
collaboration is increasing and pooling of research resources is necessary to conduct 
research on complex diseases and health, it is difficult for the bioresource to keep track of 
all eventual users. The identity of the source of a material may be lost in the chain of 
multiple exchanges and amalgamation with others. A bioresource can thus require that 
users do not share with third parties the material/data. Under such circumstances, it is 
expected that eventual users will have to deal directly with the initial bioresource 
provider to gain access, and will thus have the same requirements imposed upon them to 
recognize the original resources. However, here again, a balance must be struck between 
imposing constraints on users and making use of the bioresources appealing. Even if the 
correct balance is struck, there are specific issues relating to databases where no physical 
entity is necessarily provided. To some extent, commercial data providers can impose 
constraints on the onward distribution of the data. A breach of corresponding terms and 
conditions might then allow the data provider to restrict future access. Among those who 
provide free access to their data some large organisations do can support a number of 
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actions [25]. Smal data providers, for example, curators of LSDBs for a small number of 
genes have fewer opportunities to exert access control and simply rely on database 
copyright protection [26]. Given the delicate balance required between stimulating uses 
and supporting the capacity to measure the impact, the BRIF sub-group proposes to 
further study and develop an appropriate set of tools that could eventually be integrated 
in the overall access and sharing policies of the bioresources. 
 
 
Conclusion 
 
There is definite pressure to develop a chart of principles, tools and guidelines for 
bioresources management, uses and referencing on which the medical and scientific 
community could rely for their research practice. However this will not become tangible 
unless proper tools and frameworks for recognising such activities are first in place. This 
forum article provides the foundations for such policies and hopes to stimulate discussion 
among relevant stakeholders.  
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
56
8.
1 
: P
os
te
d 
4 
No
v 
20
11
 BRIF DRAFT Manuscript 04/11/11 
 7 
Box 1: Definitions. 
 
*Organisation for Economic Co-operation and Development 
** From National Cancer Institute Best Practices for Biospecimen Resources 
Biospecimen.: A quantity of tissue, blood, urine, or other human-derived material. A biospecimen can 
comprise subcellular structures, cells, tissue (e.g. bone, muscle, connective tissue, and skin), organs (e.g., 
liver, bladder, heart, and kidney), blood, gametes (sperm and ova), embryos, fetal tissue, and waste (urine, 
feces, sweat, hair and nail clippings, shed epithelial cells, and placenta). Portions or aliquots of a 
biospecimen are referred to as samples (NCI** Best Practices working definition).  
Database: An organized set of data or collection of files that can be used for a specified purpose (definition 
from A dictionary of Epidemiology 4th Ed. by J.M. Last) 
Biorepository. An organization, place, room, or container (a physical entity) where biospecimens are stored 
(NCI** Best Practices working definition). 
Biological resource centres: consist of service providers and repositories of the living cells, genomes of 
organisms, and information relating to heredity and the functions of biological systems. BRCs contain 
collections of culturable organisms (e.g. genomes, plasmids, viruses, cDNAs), viable but not yet culturable 
organisms cells and tissues, as well as databases containing molecular, physiological and structural 
information relevant to these collections and related bioinformatics… 
Biospecimen resource. A collection of human specimens and associated data for research purposes, the 
physical entity in which the collection is stored, and all associated processes and policies. Biospecimen 
resources vary considerably, ranging from formal institutions to informal collections in a researcher’s 
freezer (NCI Best Practices working definition). 
Bioresources : include both biological samples with associated data (medical/epidemiological, social), 
databases independent of physical samples and other biomolecular and bioinformatics research tools (BRIF 
group working definition). 
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Box 2: Examples of indicators describing an efficient bioresource management and 
use. 
 
 
 
 
Box 3: Current key elements impeding proper tracking of bioresources use in scientific 
literature. 
 
*Peterson & Campbell  Nature Genetics  42 (11), 919 (2010). 
 
 
 
 
 
 
 
 
►Indicators of management: 
- Number of projects supported per year 
- Number of biospecimens entering in the biobank / number of biospecimens used for 
developing a research project by year  
- Sustainable maintenance  
 
►Indicators of quality: 
- Participation in external assessment programmes such as certification or accreditation 
- Performing a morphological control of frozen specimens used for “omics” programme 
(biobanks)  
- Assessment of the extent and richness of the datasets collected (including follow up of 
patients and treatments when relevant) 
 
►Indicators of research productivity: 
- Counting and measuring  
- The cumulated impact of publications that result from research supported by the 
bioresource 
- The number of patents that result from the use of the bioresource 
- The number of material (data) transfer agreements and contracts signed per year 
 
Difficulties related to identification and acknowledgement of bioresources: 
- multiplicity of sections where bioresources can be acknowledged (Material & 
Methods, Acknowledgements, References…) 
- bioresource acknowledgement or citation placed outside the title or abstract in the 
main paper (or in online supplementary materials) and can therefore only be 
detected via full-text mining and is not indexed in Pubmed or Web of Science 
- typing errors or approximation of the bioresource name/identification 
- multiplicity of names for a given bioresource 
- acknowledgement of persons instead of the bioresource itself 
- absence of acknowledgement for the bioresource used (negligence) 
- no standardized way to incentivise researchers to acknowledge properly the 
bioresource used 
- …. 
 
Difficulties encountered with marker papers*: 
-Suitable to refer to one type of bioresource but not for any derived, or secondary 
bioresources   
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Box 4: Possible BRIF parameters to take into consideration. 
 
First-line parameters 
 
                    
Second-line parameters 
 
 
a/ Indicators of research productivity: 
- Number of articles citing the bioresource itself or 
the staff 
- The quality of the journal (impact factor...) 
 
-Grants obtained by the users of the bioresource or to 
support the bioresource 
- Patents/licenses based on research supported by the 
bioresource 
- Economic impact 
 
b/ Indicators of quality 
-Richness of data associated with samples 
-Compliance with data reporting nomenclatures and 
sharing standards 
 
 
-Official recognition from Regional/National Health 
Institution  
 
c/ Indicators of high value  
- Depth of data associated with samples  
- Rare disease samples or data 
- Existence of a quality control policy for samples 
and data 
 
 
d/ Indicators of usage 
- Number of requests filed per year (to be balanced 
with the type of resource) 
- Number of web page accesses per year for data 
resources 
 
- Number of samples received and distributed per year 
- Number of material/data transfer agreements 
- Number of contracts or conventions 
 
e/ Indicators of ethical standards  
- General policies of transparency, access rules, use 
of appropriate MTAs/DTAs 
- Consent forms 
- Data protection measures 
 
 
f/ Indicators of biobank efficiency 
- Turnaround time for requests 
- Time to include new data 
 
 
Other factors 
- Age of bioresource 
- Size of bioresource   
- Return of research policy 
- impact of data cost on inclination to correctly cite 
the source of data  
- Past achievements of the bioresource…  
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Box 5: Main suggestions for the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals: Writing and Editing for Biomedical Publication (www.icmje.org): 
 
 
 
 
 
in II. ETHICAL CONSIDERATIONS IN THE CONDUCT AND REPORTING OF 
RESEARCH 
II.A Authorship and contributorship 
II.A.2 Contributors listed in acknowledgements: 
Proposition: ‘Biobankers should always be acknowledged for their contribution in 
providing "bioresources" useful for the conduct of the study. The name of the biobank 
(and identifier, if available) should also be reported here in full.’ 
 
in IV. MANUSCRIPT PREPARATION AND SUBMISSION 
 IV.A Preparing a manuscript for submission to a biomedical journal 
  IV.A.2 Title page 
Propositions:  
‘8. List of bioresources and/or biobanks used as sources of samples and/or data (and 
their identifier, if available).  Bioresources include both biological samples with 
associated data (medical/epidemiological, social) and biomolecular research tools. The 
biosamples and biomolecular resources include any "physical" specimen derived from 
biological organisms, as well as antibody, affinity binder collections, clone collections, 
siRNA and microarrays libraries. Research tools include any data directly or 
undirectly derived from biosamples such as databases, locus specific-databases, 
registries of disease patients and any specific tool for molecular characterization of 
biobanked samples.’ 
 
‘9. Infrastructures. National, European and/or international infrastructure that has 
evaluated the project.’ 
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